MDMA isn’t Psychedelic
MDMA, or 3,4-Methylenedioxymethamphetamine, is not a psychedelic, though it is commonly grouped with them. The “MA” in MDMA stands for methamphetamine because this drug is a stimulant that energizes users, making them want to dance, move, or connect with other humans.
It can cause mild hallucinations, but nothing on the scale of psilocybin or LSD. It doesn’t cause ego-death or a substantially altered state of consciousness. Nevertheless, multiple credible sources list MDMA as a psychedelic, including both the DEA and the National Institute on Drug Abuse (NIDA).
MDMA is an Amphetamine
Despite the porosity of our drug classification system, Americans would be better off if we listed MDMA as an amphetamine, rather than a psychedelic. Psychedelics have a reputation as intense drugs with a low potential for any long-term harm, which is why MDMA tends to be placed there. These drugs can be used by curious, fun-seeking people who seek to expand their consciousness, usually while communing with nature.
Amphetamines, on the other hand, don’t enjoy a reputation for harmlessness. These drugs are more often enjoyed by members of lower socio-economic groups in rural or economically-depressed areas. Methamphetamine usage is often associated with stronger patterns of dependence and criminal justice involvement. To be blunt, we call MDMA a psychedelic because pretty, white girls like it. What would it mean for Becky if she found out that she liked the same kind of drugs as poor people?
The drugs themselves are not the problem; it’s our perception that gums up the works. Psychedelics are often used by affluent people seeking healing, however they understand that. Amphetamines and methamphetamine can be used to treat ADHD or binge-eating disorder, which means that their medical potential is just as valid.
Ultimately, drug classifications should reflect pharmacology, not prejudice or cultural bias. Calling MDMA a psychedelic instead of an amphetamine doesn’t change what it does in the brain. When we rely on socially convenient labels instead of scientific accuracy, we create stigma, obscure risks, and make it harder for patients, clinicians, and policymakers to make informed decisions. If we want a more honest conversation about drugs, we have to start by acknowledging that our categories are imperfect, and sometimes, they’re designed to protect the illusions of the elite.